Drug Approval | January 23, 2023
Astellas announces hold lifted by FDA on Fortis clinical trial of AT845
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
The new project further expands the partner's long-term collaboration on new technologies for R&D
The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens
A study by Agharkar Research Institute (ARI), Pune, has discovered that a protein secreted from intervertebral disc cells induces disc regeneration in aged degenerated discs
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
Subscribe To Our Newsletter & Stay Updated
